Alk-Abello AS Class B ALK B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 50.75
- Price/Sales
- 7.12
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,806
- Website
- https://www.alk.net
Comparables
Valuation
|
Metric
|
ALK B
|
HLUN A
|
NOVO B
|
|---|---|---|---|
Price/Earnings (Normalized) | 50.75 | 7.57 | 39.67 |
Price/Book Value | 7.72 | 1.62 | 31.53 |
Price/Sales | 7.12 | 1.82 | 13.82 |
Price/Cash Flow | 31.03 | 7.19 | 31.53 |
Price/Earnings
ALK B
HLUN A
NOVO B
Financial Strength
|
Metric
|
ALK B
|
HLUN A
|
NOVO B
|
|---|---|---|---|
Quick Ratio | 1.15 | 1.32 | 0.74 |
Current Ratio | 2.67 | 1.88 | 0.94 |
Interest Coverage | — | — | 30.52 |
Quick Ratio
ALK B
HLUN A
NOVO B
Profitability
|
Metric
|
ALK B
|
HLUN A
|
NOVO B
|
|---|---|---|---|
Return on Assets (Normalized) | 10.84% | 11.51% | 28.75% |
Return on Equity (Normalized) | 16.13% | 19.52% | 89.64% |
Return on Invested Capital (Normalized) | 14.00% | 15.80% | 67.68% |
Return on Assets
ALK B
HLUN A
NOVO B
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gpgyhhfxz | Chcjl | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wdmllcm | Zddcjv | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rvlynxkvc | Krgcrpp | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vbjppgth | Jvfdw | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Nglklclt | Cfnm | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bhnfzllc | Gwj | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vgwyvtvmv | Sjfg | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pnmqsjd | Dhvyj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wgxxsybv | Znsghy | $13.4 Bil | |||
| Incyte Corp
INCY
| Gwcfdqylf | Kxsntzh | $12.7 Bil |
United States